Bristol-Myers Squibb Co.

NYSE:BMY   10:46:01 AM EDT
+0.18 (+0.28%)
Products, Strategic Combinations

Century Therapeutics, Bristol Myers Enter Collaboration To Develop IPSC-Derived Allogeneic Cell Therapies

Published: 01/10/2022 13:01 GMT
Bristol-Myers Squibb Co. (BMY) - Century Therapeutics and Bristol Myers Squibb Enter Into a Strategic Collaboration to Develop Ipsc-derived Allogeneic Cell Therapies.
Bristol Myers - Century Will Receive $150 Million in Cash; $100 Million Upfront Payment and $50 Million Equity Investment at $23.14/share.
Bristol Myers - Century Therapeutics Has Potential for Additional $3 Billion in Payments Plus Royalties.
Bristol Myers - First Two Programs Under Collaboration With Century Include a Program in Acute Myeloid Leukemia and a Program in Multiple Myeloma.
Bristol Myers - Co Has Option to Add Two Additional Programs Which Can Be Nominated Subject to Certain Conditions Agreed With Century in Agreement.
Bristol Myers - Century Amended Agreements With Fujifilm Cellular Dynamics for Japanese Rights for Products Under Collaboration With Co.
Bristol Myers - Century May Elect to Co Promote the Aml Program and One of the Additional Programs in U.S. for No Exercise Fee.
Bristol Myers - Century Will Be Responsible for Development Candidate Discovery and Preclinical Development Activities.
Bristol Myers - Century Therapeutics Will Also Receive Tiered Royalties As a Percentage of Global Net Sales in High-single to Low-double Digits.
Bristol Myers - Co to Be Responsible for Clinical Development, Commercialization Activities Subject to Century’s Co-promotion Rights on Some Programs.